Wells Fargo & Company Vaccinex, Inc. Transaction History

Wells Fargo & Company

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 15, 2023	BUY	$0.34 - $0.48 $20 - $28	59 Added 30.73%	251 $0
Q1 2023 May 12, 2023	BUY	$0.39 - $0.65 $1 - $1	3 Added 1.59%	192 $0
Q4 2022 Feb 13, 2023	BUY	$0.44 - $131.17 $2 - $655	5 Added 2.72%	189 $0
Q3 2022 Nov 14, 2022	SELL	$0.48 - $109.22 $7 - $1,747	-16 Reduced 8.0%	184 $0
Q2 2022 Aug 12, 2022	BUY	$1.05 - $1.39 $94 - $125	90 Added 81.82%	200 $0
Q4 2021 Feb 14, 2022	BUY	$1.04 - $2.12 $9 - $19	9 Added 8.91%	110 $0
Q3 2021 Nov 15, 2021	BUY	$2.11 - $2.81 $8 - $11	4 Added 4.12%	101 $0
Q2 2021 Aug 16, 2021	BUY	$2.01 - $3.0 $78 - $117	39 Added 67.24%	97 $0
Q4 2020 Feb 09, 2021	BUY	$1.66 - $2.35 $26 - $37	16 Added 38.1%	58 $0
Q3 2020 Nov 05, 2020	BUY	$1.75 - $8.19 $31 - $147	18 Added 75.0%	42 $0
Q1 2020 May 14, 2020	BUY	$3.96 - $8.37 $95 - $200	24 New	24 $0

426K

Ticker VCNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,664,100
Market Cap $240M
Description
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab,...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.